SCHEMBL7301929

SCHEMBL7301929

O=C(O)CN(Cc1ccccc1)C(=O)O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.55
ALDH1A1 P00352 3/20 0.53
NPSR1 Q6W5P4 1/20 0.53
TSHR P16473 1/20 0.52
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
TDP1 Q9NUW8 1/20 0.50
KDM4E B2RXH2 1/20 0.50
MGLL Q99685 1/20 0.48
AKR1B1 P15121 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.47
MAPT P10636 1/20 0.47
REN P00797 1/20 0.47
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
CA12 O43570 1/20 0.47
CA9 Q16790 1/20 0.47
HDAC3 O15379 2/20 0.47
HDAC1 Q13547 2/20 0.47
HDAC7 Q8WUI4 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL825414 0.86 LMNA (0.63) LMNAALDH1A1NPSR1TSHRMEN1
SCHEMBL27620333 0.86 KDM4E (0.54) LMNAALDH1A1NPSR1TSHRMEN1
SCHEMBL5190596 0.86 CTSS (0.59) LMNATSHRMEN1KMT2ATDP1
SCHEMBL11378089 0.86 LMNA (0.55) LMNAALDH1A1NPSR1TSHRMEN1
SCHEMBL7397340 0.84 LMNA (0.57) LMNAALDH1A1NPSR1TSHRMEN1
SCHEMBL6314244 0.84 LMNA (0.49) LMNAALDH1A1NPSR1TSHRMEN1
SCHEMBL6314236 0.84 LMNA (0.49) LMNAALDH1A1NPSR1TSHRMEN1
SCHEMBL638764 0.84 LMNA (0.61) LMNAALDH1A1NPSR1TSHRMEN1
SCHEMBL8718249 0.84 LMNA (0.61) LMNAALDH1A1NPSR1TSHRMEN1
SCHEMBL673623 0.84 LMNA (0.61) LMNAALDH1A1NPSR1TSHRMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9045513-B2 Method for preparing precursor used for labeling hepatocyte receptor and containing trisaccharide and DTPA ligand Atomic Energy Council—Institute of Nuclear Energy Research (TW) 2015-06-02 US disclosed
US-20140046045-A1 METHOD FOR PREPARING PRECURSOR USED FOR LABELING HEPATOCYTE RECEPTOR AND CONTAINING TRISACCHARIDE AND DTPA LIGAND ATOMIC ENERGY COUNCIL - INSTITUTE OF NUCLEAR ENERGY RESEARCH (TW) 2014-02-13 US disclosed
CN-102532127-A Improved method for synthetizing novel P38 mitogen-activated protein kinase inhibitor SHANGHAI AINAKE BIOMEDICINE TECHNOLOGY CO LTD 2012-07-04 CN disclosed
EP-0871619-B1 PHENYL THIAZOLE DERIVATIVES WITH ANTI HERPES VIRUS PROPERTIES BOEHRINGER INGELHEIM PHARMA (US) 2002-11-06 EP disclosed
US-6458959-B1 VIRICIDES AND ENZYME INHIBITORS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2002-10-01 US disclosed
US-6348477-B1 SUBSTITUTED PHENYL THIAZOLE DERIVATIVES AS VIRICIDES BOEHRINGER INGELHEIM(CANADA) LTD. (CA) 2002-02-19 US disclosed
US-6288091-B1 COMPOUNDS SUCH AS 2,2,2-TRICHLOROETHYL N-(4-(2-AMINO-4-THIAZOLYL)-PHENYL)CARBAMATE THAT INHIBIT THE HERPES HELCASE-PRIMASE ENZYME COMPLEX BOEHRINGER INGELHEIM LTD. (CA) 2001-09-11 US disclosed
US-6057451-A AMINOTHIAZOLE DERIVATIVES BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2000-05-02 US disclosed
EP-0871619-A1 PHENYL THIAZOLE DERIVATIVES WITH ANTI HERPES VIRUS PROPERTIES BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) 1998-10-21 EP disclosed
WO-1997024343-A1 PHENYL THIAZOLE DERIVATIVES WITH ANTI HERPES VIRUS PROPERTIES BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 1997-07-10 WO disclosed
US-5428009-A Antibiotics, fungicides, and antiprotozoa agents MERCK & CO., INC. (US) 1995-06-27 US disclosed
US-5385884-A Water-soluble, injectible echinocandins; fungicides; antiprotozoa agents, yeasts MERCK & CO. INC. (US) 1995-01-31 US disclosed
US-5369093-A Antibiotic lipopeptides as fungicides and antiprotozoa agents MERCK & CO., INC. (US) 1994-11-29 US disclosed
US-5330973-A Fungicides, antiprotozoa agents MERCK & CO., INC. (US) 1994-07-19 US disclosed
EP-0503960-A1 Cyclic lipopeptides having antibiotic activity MERCK & CO. INC. (US) 1992-09-16 EP disclosed
EP-0448354-A2 Lipopeptide derivatives MERCK & CO. INC. (US) 1991-09-25 EP disclosed
EP-0448343-A2 Lipopeptide derivatives MERCK & CO. INC. (US) 1991-09-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140046045-A1 METHOD FOR PREPARING PRECURSOR USED FOR LABELING HEPATOCYTE RECEPTOR AND CONTAINING TRISACCHARIDE AND DTPA LIGAND HDGF, NR1H4, TRHR LMNA 2172/4885ALDH1A1 4339/4885NPSR1 41/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.